Skip to main content
SpringerLink
Log in

Viral Hepatitis: Hepatitis C

  • Chapter
  • First Online:
Book cover Liver Disorders

  • 1650 Accesses

Abstract

Perhaps no field in medicine has evolved more rapidly in the past decade than that of treatment of hepatitis C. With the availability of myriad new options, management of those infected with hepatitis C has been transformed and while some questions remain regarding treatment regimens for special populations (e.g., those with renal failure), eradication of the virus for most patients is now feasible with response rates to the new regimens exceeding 90 % for the majority of patients. Unfortunately, access to and cost of medications pose significant barriers for treatment. In light of this rapid evolution, this chapter focuses on questions a patient or provider may encounter in terms of risk factors, clinical presentation as well as natural history, and delves into specific treatment options including addressing options available to special populations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view.

  2. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37(10):921–36.

    Article  CAS  PubMed  Google Scholar 

  3. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103(5):1283–97. quiz 98.

    Article  PubMed  Google Scholar 

  4. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196(10):1474–82.

    Article  PubMed  Google Scholar 

  5. Bunchorntavakul C, Jones LM, Kikuchi M, Valiga ME, Kaplan DE, Nunes FA, et al. Distinct features in natural history and outcomes of acute hepatitis C. J Clin Gastroenterol. 2015;49(4):e31–40.

    Google Scholar 

  6. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol. 2012;57(6):1349–60.

    Article  PubMed  Google Scholar 

  7. Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther. 2011;33(5):559–65.

    Article  CAS  PubMed  Google Scholar 

  8. Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology. 2012;55(6):1684–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139(5):1586–92. 92 e1.

    Article  CAS  PubMed  Google Scholar 

  10. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80–8.

    Article  PubMed  Google Scholar 

  11. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43(9):1154–9.

    Article  CAS  PubMed  Google Scholar 

  12. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43(5):923–31.

    Article  CAS  PubMed  Google Scholar 

  13. European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014.

  14. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–64.

    Article  Google Scholar 

  15. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130(3):632–8.

    Article  CAS  PubMed  Google Scholar 

  16. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, et al. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology. 2014;59(6):2101–9.

    Article  CAS  PubMed  Google Scholar 

  17. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250–6.

    Article  CAS  PubMed  Google Scholar 

  18. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17(3):201–7.

    Article  CAS  PubMed  Google Scholar 

  19. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–31.

    Article  PubMed  Google Scholar 

  20. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008;134(6):1699–714.

    Article  CAS  PubMed  Google Scholar 

  21. Goossens N, Negro F. The impact of obesity and metabolic syndrome on chronic hepatitis C. Clin Liver Dis. 2014;18(1):147–56.

    Article  PubMed  Google Scholar 

  22. Inglesby TV, Rai R, Astemborski J, Gruskin L, Nelson KE, Vlahov D, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999;29(2):590–6.

    Article  CAS  PubMed  Google Scholar 

  23. Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182(6):1595–601.

    Article  CAS  PubMed  Google Scholar 

  24. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009;30(6):557–76.

    Article  CAS  PubMed  Google Scholar 

  25. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C—natural history and cofactors. Aliment Pharmacol Ther. 2005;22 Suppl 2:74–8.

    Article  PubMed  Google Scholar 

  26. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.

    Article  PubMed  Google Scholar 

  27. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24 Suppl 2:3–8.

    Article  PubMed  Google Scholar 

  28. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017–29.

    Article  PubMed  Google Scholar 

  29. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39(1):2–17.

    Article  CAS  PubMed  Google Scholar 

  30. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231–7.

    Article  CAS  PubMed  Google Scholar 

  31. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Seeff LB. Sustained virologic response: is this equivalent to cure of chronic hepatitis C? Hepatology. 2013;57(2):438–40.

    Article  PubMed  Google Scholar 

  33. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology. 2009;49(2):665–75.

    Article  PubMed  Google Scholar 

  34. Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–83.

    Article  CAS  PubMed  Google Scholar 

  35. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104(10):2439–48.

    Article  CAS  PubMed  Google Scholar 

  36. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135(3):821–9.

    Article  PubMed  Google Scholar 

  37. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–8. 8 e1.

    Article  PubMed  Google Scholar 

  39. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.

    Article  PubMed  Google Scholar 

  40. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.

    Article  CAS  PubMed  Google Scholar 

  41. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138(1):116–22.

    Article  CAS  PubMed  Google Scholar 

  42. Rumi MG, Aghemo A, Prati GM, D’Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108–15.

    Article  CAS  PubMed  Google Scholar 

  43. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93.

    Article  CAS  PubMed  Google Scholar 

  44. Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: a concise review and response-guided therapy proposal. World J Hepatol. 2013;5(9):496–504.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139(6):1865–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.

    Article  CAS  PubMed  Google Scholar 

  47. Bunchorntavakul C, Reddy KR. Ribavirin: how does it work and is it still needed? Curr Hepatitis Rep. 2011;10:168–78.

    Article  Google Scholar 

  48. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139(5):1602–11. 11 e1.

    Article  PubMed  Google Scholar 

  49. Kiser JJ, Burton Jr JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60(4):872–84.

    Article  CAS  PubMed  Google Scholar 

  51. Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol. 2008;103(8):2123–34.

    Article  PubMed  Google Scholar 

  52. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14(10):697–703.

    CAS  PubMed  Google Scholar 

  53. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol. 2011;26(2):228–39.

    Article  CAS  PubMed  Google Scholar 

  54. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis. 2004;43(1):131–9.

    Article  PubMed  Google Scholar 

  55. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257–63.

    Article  CAS  PubMed  Google Scholar 

  56. Al-Freah MA, Zeino Z, Heneghan MA. Management of hepatitis C in patients with chronic kidney disease. Curr Gastroenterol Rep. 2012;14(1):78–86.

    Article  PubMed  Google Scholar 

  57. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48(5):1690–9.

    Article  CAS  PubMed  Google Scholar 

  58. Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014;39(10):1213–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J Clin Translational Hepatol. 2014;2:124–33.

    Article  Google Scholar 

  60. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int. 2012;32 Suppl 1:120–8.

    Article  CAS  PubMed  Google Scholar 

  61. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–41.

    Article  PubMed  Google Scholar 

  62. Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2015;62(2):286–93.

    Article  CAS  PubMed  Google Scholar 

  63. Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal NH, editors. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) November 1–5, 2014; Boston, MA.

    Google Scholar 

  64. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36–44.

    Article  PubMed  Google Scholar 

  65. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009;9(8):1707–13.

    Article  CAS  PubMed  Google Scholar 

  66. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60(1):78–86.

    Article  CAS  PubMed  Google Scholar 

  67. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7.

    Article  PubMed  Google Scholar 

  68. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis. 2003;7(1):179–94.

    Article  PubMed  Google Scholar 

  69. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138(3):197–207.

    Article  PubMed  Google Scholar 

  70. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.

    Article  PubMed  Google Scholar 

  71. Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS. 2012;26(17):2241–6.

    Article  PubMed  Google Scholar 

  72. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196(5):670–6.

    Article  CAS  PubMed  Google Scholar 

  73. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48(2):353–67.

    Article  CAS  PubMed  Google Scholar 

  74. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–31.

    Article  CAS  PubMed  Google Scholar 

  75. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38(8):e79–80.

    Article  CAS  PubMed  Google Scholar 

  76. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13(10):683–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Conflict of Interest: KRR: Advisory Board: Abbvie, Merck, Gilead, BMS, and Janssen. Grant support paid to the University of Pennsylvania: Abbvie, Merck, Gilead, BMS, and Janssen. CB: Nothing to disclose.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Hospital of the University of Pennsylvania, 2 Dulles, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Chalermrat Bunchorntavakul M.D. & K. Rajender Reddy M.D.

  2. Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Rajavithi Road, Ratchathewi, Bangkok, 10400, Thailand

    Chalermrat Bunchorntavakul M.D.

Authors
  1. Chalermrat Bunchorntavakul M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Rajender Reddy M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Rajender Reddy M.D. .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, Wisconsin, USA

    Kia Saeian

  2. Division of Gastroenterology and Hepatology, Medicine Medical College of Wisconsin , Milwaukee, Wisconsin, USA

    Reza Shaker

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bunchorntavakul, C., Reddy, K.R. (2017). Viral Hepatitis: Hepatitis C. In: Saeian, K., Shaker, R. (eds) Liver Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-30103-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30103-7_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30101-3

  • Online ISBN: 978-3-319-30103-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation